Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Azuma, Science University, Tokyo), and human IgM-Fc (Rockland, Gilbertsville, PA) were used. Monoclonal antibodies to human CD3, CD45 and CD71, and M18-254 were purchased from PharMingen (San ...

IGM-2644 or CD38 x CD3, a bispecific IgM monoclonal antibody that targets CD3 and CD38 proteins. It has 10 CD38 binding sites and an anti-CD3epsilon single chain variable fragment or scFv domain.

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, ...

Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...

Normally, cells take up antigens bound to immunoglobulin G (IgG) from the bloodstream and shuttle them to endosomes ... a molecular biologist from Liverpool School of Tropical Medicine who was not ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for the clinical-stage anti-immunoglobulin E (IgE) monoclonal antibody, RPT904, designed to treat various ...